AIRLINK 196.85 Increased By ▲ 3.29 (1.7%)
BOP 10.15 Increased By ▲ 0.20 (2.01%)
CNERGY 7.76 Decreased By ▼ -0.17 (-2.14%)
FCCL 40.10 Decreased By ▼ -0.55 (-1.35%)
FFL 17.02 Increased By ▲ 0.16 (0.95%)
FLYNG 27.18 Decreased By ▼ -0.57 (-2.05%)
HUBC 133.51 Increased By ▲ 0.93 (0.7%)
HUMNL 13.96 Increased By ▲ 0.07 (0.5%)
KEL 4.72 Increased By ▲ 0.12 (2.61%)
KOSM 6.63 Increased By ▲ 0.01 (0.15%)
MLCF 47.45 Decreased By ▼ -0.15 (-0.32%)
OGDC 214.00 Increased By ▲ 0.09 (0.04%)
PACE 6.95 Increased By ▲ 0.02 (0.29%)
PAEL 41.75 Increased By ▲ 0.51 (1.24%)
PIAHCLA 16.96 Decreased By ▼ -0.19 (-1.11%)
PIBTL 8.50 Increased By ▲ 0.09 (1.07%)
POWER 9.40 Decreased By ▼ -0.24 (-2.49%)
PPL 183.40 Increased By ▲ 1.05 (0.58%)
PRL 42.09 Increased By ▲ 0.13 (0.31%)
PTC 24.98 Increased By ▲ 0.08 (0.32%)
SEARL 109.65 Increased By ▲ 2.81 (2.63%)
SILK 0.99 No Change ▼ 0.00 (0%)
SSGC 42.80 Increased By ▲ 2.70 (6.73%)
SYM 18.39 Increased By ▲ 0.92 (5.27%)
TELE 8.90 Increased By ▲ 0.06 (0.68%)
TPLP 13.01 Increased By ▲ 0.26 (2.04%)
TRG 67.21 Increased By ▲ 0.26 (0.39%)
WAVESAPP 11.50 Increased By ▲ 0.17 (1.5%)
WTL 1.80 Increased By ▲ 0.01 (0.56%)
YOUW 4.00 Decreased By ▼ -0.07 (-1.72%)
BR100 12,216 Increased By 171 (1.42%)
BR30 36,778 Increased By 198.4 (0.54%)
KSE100 115,210 Increased By 1171.7 (1.03%)
KSE30 36,220 Increased By 425.7 (1.19%)
Markets

Bayer to cut more than 1.5bn euros in costs

  • The cash flow freed up would be allocated for investments in further innovation, profitable growth opportunities and debt reduction.
  • Bayer said it expects 2021 sales to be about the same as in 2020, despite significant headwinds from COVID-19.
Published September 30, 2020

BERLIN: German drugs company Bayer AG announced plans on Wednesday for more than 1.5 billion euros ($1.76 billion)of cost cuts as of 2024, on top of savings announced in 2018, as it battles with a slowdown in the agricultural market.

The cash flow freed up would be allocated for investments in further innovation, profitable growth opportunities and debt reduction. It said the restructuring, which may also lead to extra job cuts, is in the early stages of planning.

Bayer said it expects 2021 sales to be about the same as in 2020, despite significant headwinds from COVID-19, especially in the agricultural market, and said it expects core earnings per share to be slightly lower at constant exchange rates.

Comments

Comments are closed.